Affiliation: Massachusetts General Hospital
- The role of interleukin-1 in the pathogenesis of rheumatoid arthritisJ Kay
Rheumatology Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
Rheumatology (Oxford) 43:iii2-iii9. 2004..Taken together, these results indicate that IL-1 plays an important role in the pathogenesis of RA...
- Imatinib mesylate treatment of nephrogenic systemic fibrosisJonathan Kay
Rheumatology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
Arthritis Rheum 58:2543-8. 2008..To examine the effectiveness of imatinib mesylate in the treatment of nephrogenic systemic fibrosis (NSF)...
- Nephrogenic systemic fibrosis: a new concern for rheumatologistsJonathan Kay
Nat Clin Pract Rheumatol 4:445. 2008
- Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skinJonathan Kay
Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, USA
N Engl J Med 358:827-38. 2008
- Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunctionJ Kay
Division of Rheumatology, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Ann Rheum Dis 67:iii66-9. 2008..Although no medical treatment has been proved to be universally effective in patients with NSF, imatinib mesylate shows potential as a therapeutic agent and is currently being studied in these patients...
- Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyJonathan Kay
Rheumatology Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
Arthritis Rheum 58:964-75. 2008..To assess the efficacy, safety, and pharmacology of subcutaneous administration of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX)...
- A rheumatology-specific informatics-based application with a disease activity calculatorDeborah S Collier
Massachusetts General Hospital, Boston, MA, USA
Arthritis Rheum 61:488-94. 2009..To design a rheumatology-specific tool with a disease activity calculator integrated into the electronic medical records (EMRs) at our institution and assess physicians' attitudes toward the use of this tool...
- Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculatorDeborah S Collier
Massachusetts General Hospital, Boston, MA, USA
Arthritis Rheum 61:495-500. 2009..To assess physicians' concordance with Disease Activity Score in 28 joints (DAS28) categories calculated by an electronic medical record (EMR)-embedded disease activity calculator, as well as attitudes toward this application...
- Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposureDerrick J Todd
Massachusetts General Hospital, Harvard Medical School, and Brigham and Women s Hospital, Boston, Massachusetts 02114, USA
Arthritis Rheum 56:3433-41. 2007..Little is known about its prevalence or etiology. The aim of this study was to establish the prevalence of NSF and associated risk factors..
- Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patientsHani H Abujudeh
Department of Radiology and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Radiology 253:81-9. 2009..To retrospectively assess the association between gadopentetate dimeglumine exposure at magnetic resonance imaging and the development of nephrogenic systemic fibrosis (NSF)...
- Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patientsHani H Abujudeh
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
J Magn Reson Imaging 30:1335-40. 2009..J. Magn. Reson. Imaging 2009;30:1335-1340. (c) 2009 Wiley-Liss, Inc...
- Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiencyJonathan Kay
Rheumatology Unit, Massachusetts General Hospital, Boston, USA
N Engl J Med 353:1605-13. 2005
- Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicityDerrick J Todd
Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Yawkey 2 174, 55 Fruit Street, Boston, MA 02114, USA
Curr Rheumatol Rep 10:195-204. 2008..In this report, we review the history of GASF, its association with prior GCCA exposure, its clinicopathologic features, the relevant pharmacology of GCCAs, the likely role of GCCAs in its pathogenesis, and potential treatments...
- Current status of nephrogenic systemic fibrosisL Daftari Besheli
Radiology Department, Massachusetts General Hospital, Harvard Medical School, USA
Clin Radiol 69:661-8. 2014..The present review introduces and compares updated guidelines for GBCA use and discusses the latest advances in the understanding of the pathogenic mechanisms and treatment of NSF. ..
- The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological reportTuhina Neogi
Boston University School of Medicine, Boston, Massachusetts, USA
Arthritis Rheum 62:2582-91. 2010..The aim of Phase 2 of the development process was to achieve expert consensus on the clinical and laboratory variables that should contribute to the final criteria set...
- Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblastsW F Owen
Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
Kidney Int 53:1365-73. 1998..These findings support the hypothesis that beta 2m-AGE actively participates in connective tissue and bone remodeling via a pathway involving fibroblast RAGE, and at least one interposed mediator, the growth factor EGF...
- Bone damage in rheumatoid arthritis: mechanistic insights and approaches to preventionSougata Karmakar
Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, UMass Memorial Medical Center, Lazare Research Building, Suite 223, 364 Plantation Street, Worcester, MA 01605, USA
Rheum Dis Clin North Am 36:385-404. 2010..In this review, the authors discuss the current understanding of pathogenic mechanisms of bone erosion in RA and examine current therapeutic approaches to prevent this damage...
- Case records of the Massachusetts General Hospital. Case 4-2006. A 79-year-old woman with myalgias, fatigue, and shortness of breathJonathan Kay
Department of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, USA
N Engl J Med 354:623-30. 2006
- Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trialStanley B Cohen
Metroplex Clinical Research Center, Dallas, Texas 75235, USA
Arthritis Rheum 58:1299-309. 2008..The aim of this multicenter, randomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment...
- Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seenJonathan Kay
Cleve Clin J Med 75:112, 114, 117. 2008
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skinSamuel L Moschella
Department of Dermatology, Lahey Clinic, Burlington, Mass, USA
N Engl J Med 351:2219-27. 2004